These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 4181434)
1. Long-acting thyroid stimulator and exophthalmos. Burke G Ann Intern Med; 1969 May; 70(5):1045-6. PubMed ID: 4181434 [No Abstract] [Full Text] [Related]
2. Studies of serum long-acting thyroid stimulator (LATS) in relation to exophthalmos after therapy for thyrotoxicosis. Hetzel BS; Mason EK; Wang HK Australas Ann Med; 1968 Nov; 17(4):307-11. PubMed ID: 4178378 [No Abstract] [Full Text] [Related]
3. Mechanisms of Graves' disease and endocrine exophthalmos. Anderson DR Am J Ophthalmol; 1969 Jul; 68(1):46-57. PubMed ID: 4895778 [No Abstract] [Full Text] [Related]
6. Observations against a causal relationship between the long-acting thyroid stimulator and ophthalmopathy in Graves' disease. McKenzie JM; McCullagh EP J Clin Endocrinol Metab; 1968 Aug; 28(8):1177-82. PubMed ID: 4175472 [No Abstract] [Full Text] [Related]
8. [Concept of endocrine ophthalmopathies]. Heberting HJ; Schwarzmann E Z Gesamte Inn Med; 1974 Sep; 29(17):712-5. PubMed ID: 4141190 [No Abstract] [Full Text] [Related]
9. The long-acting thyroid stimulator and the result of I 131 treatment for thyrotoxicosis. Martin FI; Larkins RG; Alford FP; Andrews JT; Greenberg PB; Melick RA; Penington JS Aust N Z J Med; 1972 May; 2(2):168-72. PubMed ID: 4116447 [No Abstract] [Full Text] [Related]
10. Neonatal hyperthyroidism and long-acting thyroid stimulator protector. Nutt J; Clark F; Welch RG; Hall R Br Med J; 1974 Dec; 4(5946):695-6. PubMed ID: 4479947 [TBL] [Abstract][Full Text] [Related]
11. [New ideas on the regulation of thyroid function by LATS (long-acting thyroid stimulator) and their repercussion on human pathology]. Strumia E Minerva Med; 1967 Nov; 58(90):3879-85. PubMed ID: 5630606 [No Abstract] [Full Text] [Related]
12. Large doses of radioiodide in Graves' disease: effect on ophthalmopathy and long-acting thyroid stimulator. Pequegnat EP; Mayberry WE; McConahey WM; Wyse EP Mayo Clin Proc; 1967 Dec; 42(12):802-11. PubMed ID: 4169552 [No Abstract] [Full Text] [Related]
13. [Treatment of hyperthyreosis]. Nagy E Orv Hetil; 2005 Feb; 146(7):325-8. PubMed ID: 15782796 [No Abstract] [Full Text] [Related]
14. PARALLEL ASSAYS OF THYROTROPHIN, LONG-ACTING THYROID STIMULATOR AND EXOPHTHALMOS-PRODUCING SUBSTANCE IN ENDOCRINE EXOPHTHALMOS AND PRETIBIAL MYXEDEMA. PIMSTONE BL; HOFFENBERG R; BLACK E J Clin Endocrinol Metab; 1964 Oct; 24():976-82. PubMed ID: 14228536 [No Abstract] [Full Text] [Related]
15. Treatment of thyrotoxicosis--the current position. I. Classification, causation and treatment. Greig WR Curr Med Res Opin; 1972; 1(3):144-52. PubMed ID: 4589708 [No Abstract] [Full Text] [Related]
16. [Hyperthyroidism and the "long acting thyroid stimulator" (LATS)]. Studer H Schweiz Med Wochenschr; 1967 May; 97(19):622-3. PubMed ID: 5632362 [No Abstract] [Full Text] [Related]
17. Hyperthyroidism. Wool MS Major Probl Clin Surg; 1980; 15():102-19. PubMed ID: 7003266 [No Abstract] [Full Text] [Related]
18. Familial incidence of long-acting thyroid stimulator (LATS) in Graves' disease. Bonnyns M; Vanhaelst L Horm Metab Res; 1972 Mar; 4(2):132. PubMed ID: 5067566 [No Abstract] [Full Text] [Related]
19. [Treatment of endocrine ophthalmopathy]. Raith L Z Allgemeinmed; 1973 Dec; 49(35):1727-30. PubMed ID: 4131142 [No Abstract] [Full Text] [Related]
20. [Significance of long-acting thyroid stimulator. Reflections on the 1st series of results]. Tourneur R; Letonturier P; Sénécal P Minerva Med; 1974 Mar; 65(19):995-8. PubMed ID: 4406464 [No Abstract] [Full Text] [Related] [Next] [New Search]